Investment House LLC Sells 4,045 Shares of Teva Pharmaceutical Industries Limited (TEVA)

Investment House LLC lowered its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 5.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 73,090 shares of the company’s stock after selling 4,045 shares during the period. Investment House LLC’s holdings in Teva Pharmaceutical Industries Limited were worth $2,428,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of TEVA. Schulhoff & Co. Inc. raised its position in shares of Teva Pharmaceutical Industries Limited by 9.5% in the first quarter. Schulhoff & Co. Inc. now owns 11,601 shares of the company’s stock valued at $372,000 after buying an additional 1,004 shares during the last quarter. Heritage Investors Management Corp raised its position in shares of Teva Pharmaceutical Industries Limited by 17.5% in the first quarter. Heritage Investors Management Corp now owns 188,990 shares of the company’s stock valued at $6,065,000 after buying an additional 28,135 shares during the last quarter. Bank Hapoalim BM raised its position in shares of Teva Pharmaceutical Industries Limited by 9.2% in the first quarter. Bank Hapoalim BM now owns 11,673 shares of the company’s stock valued at $375,000 after buying an additional 980 shares during the last quarter. M Holdings Securities Inc. bought a new position in shares of Teva Pharmaceutical Industries Limited during the fourth quarter worth approximately $491,000. Finally, Migdal Insurance & Financial Holdings Ltd. raised its position in shares of Teva Pharmaceutical Industries Limited by 21.3% in the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 4,564,560 shares of the company’s stock worth $165,461,000 after buying an additional 801,106 shares in the last quarter. 56.04% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Limited (NYSE TEVA) traded up 1.17% during midday trading on Friday, hitting $17.30. The stock had a trading volume of 9,162,890 shares. The company has a 50-day moving average of $27.46 and a 200-day moving average of $30.98. The stock’s market cap is $17.58 billion. Teva Pharmaceutical Industries Limited has a 1-year low of $16.81 and a 1-year high of $53.96.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.06 by $0.07. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The company had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.72 billion. During the same quarter in the prior year, the firm earned $1.25 EPS. Teva Pharmaceutical Industries Limited’s quarterly revenue was up 12.9% compared to the same quarter last year. Equities research analysts forecast that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 14th. Investors of record on Tuesday, August 29th will be given a dividend of $0.085 per share. This represents a $0.34 annualized dividend and a dividend yield of 1.97%. The ex-dividend date is Friday, August 25th. Teva Pharmaceutical Industries Limited’s dividend payout ratio is currently -18.95%.

ILLEGAL ACTIVITY NOTICE: This news story was reported by BNB Daily and is owned by of BNB Daily. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.baseball-news-blog.com/2017/08/19/investment-house-llc-sells-4045-shares-of-teva-pharmaceutical-industries-limited-teva-updated-updated-updated.html.

A number of research analysts have recently commented on the company. BidaskClub lowered Teva Pharmaceutical Industries Limited from a “sell” rating to a “strong sell” rating in a report on Wednesday. Citigroup Inc. lowered Teva Pharmaceutical Industries Limited from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $32.00 to $19.00 in a report on Wednesday. Zacks Investment Research lowered Teva Pharmaceutical Industries Limited from a “hold” rating to a “strong sell” rating in a report on Wednesday, August 9th. Deutsche Bank AG restated a “buy” rating and set a $28.00 target price (down previously from $43.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, August 9th. Finally, Jefferies Group LLC restated a “hold” rating and set a $26.00 target price (down previously from $33.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, August 9th. Three investment analysts have rated the stock with a sell rating, twenty have issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $36.73.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply